Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
Hormonal Therapy for Gynecological Cancer
share announcement

Hormonal Therapy for Gynecological Cancer

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Survivorship and Quality of Life".

Deadline for manuscript submissions: closed (20 July 2022) | Viewed by 13241

Special Issue Editors

Dr. Simon Langdon

E-Mail Website
Guest Editor
Cancer Research UK Edinburgh Centre, MRC Institute of Genetics and Molecular Medicine, University of Edinburgh, Crewe Road South, Edinburgh EH4 2XR, UK
Interests: ovarian cancer; cell signaling; experimental therapeutics
Special Issues, Collections and Topics in MDPI journals
Prof. Charlie Gourley

E-Mail Website
Guest Editor
Cancer Research UK Edinburgh Centre, MRC Institute of Genetics and Molecular Medicine, University of Edinburgh, Crewe Road South, Edinburgh EH4 2XR, UK
Interests: ovarian cancer; cell signaling; experimental therapeutics

Special Issue Information

Dear Colleagues,

Hormonal therapies such as anti-estrogen and progestin treatments can provide clinical benefit for selected subgroups of gynecological cancer. These represent an alternative to chemotherapy when drug resistance develops or is present at the outset. For ovarian cancer, subsets of high-grade serous, low-grade serous, endometrioid cancers, and granulosa cell tumors have been shown to respond to anti-estrogen therapy. Responsiveness to progestational agents and LHRH agonists has also been demonstrated. In endometrial cancer, both progestin and anti-estrogen therapies can provide clinical benefit. Ongoing studies are seeking to identify biomarkers that may help identify patients who will benefit from these therapies.

This Special Issue of Cancers encompasses new research articles and timely reviews on the use of hormonal therapy in gynecological cancers.

Dr. Simon Langdon
Prof. Charlie Gourley
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • ovarian cancer
  • endometrial cancer
  • estrogen
  • anti-estrogens

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

18 pages, 326 KiB  
Review
New Insights into Hormonal Therapies in Uterine Sarcomas
by Elena Maccaroni, Valentina Lunerti, Veronica Agostinelli, Riccardo Giampieri, Laura Zepponi, Alessandra Pagliacci and Rossana Berardi
Cancers 2022, 14(4), 921; https://0-doi-org.brum.beds.ac.uk/10.3390/cancers14040921 - 12 Feb 2022
Cited by 10 | Viewed by 3569
Abstract
Uterine sarcoma (US) is a rare mesenchymal malignant cancer type, accounting for 3–7% of uterine malignancies. US prognosis is still poor due to high local and distant recurrence rates. As for molecular features, US may present variable oestrogen receptor (ER) and progesterone receptor [...] Read more.
Uterine sarcoma (US) is a rare mesenchymal malignant cancer type, accounting for 3–7% of uterine malignancies. US prognosis is still poor due to high local and distant recurrence rates. As for molecular features, US may present variable oestrogen receptor (ER) and progesterone receptor (PR) expressions, mostly depending on histotype and grading. Surgery represents the mainstay of treatment for early-stage disease, while the role of adjuvant chemotherapy or local radiotherapy is still debated and defined on the basis of histotype, tumour grading and stage. In metastatic setting, uterine sarcomas’ treatment includes palliative surgery, a metastases resection, chemotherapy, hormonal therapy and targeted therapy. As for the chemotherapy regimen used, drugs that are considered most effective are doxorubicin (combined with ifosfamide or alone), gemcitabine combined with docetaxel and, more recently, trabectedin or pazopanib. Hormonal therapies, including aromatase inhibitors (AIs), progestins and gonadotropin-releasing hormone analogues (GnRH-a) may also represent an effective option, in particular for low-grade endometrial stromal sarcoma (LGESS), due to their favourable toxicity profile and patients’ compliance, while their role is still under investigation in uterine leiomyosarcoma (uLMS), high-grade endometrial stromal sarcoma (HGESS), undifferentiated uterine sarcoma (USS) and other rarer US. The present review aims to analyse the existing evidence and future perspectives on hormonal therapies in US, in order to clarify their potential role in daily clinical practice. Full article
(This article belongs to the Special Issue Hormonal Therapy for Gynecological Cancer)
26 pages, 1874 KiB  
Review
Hormonal Therapy for Gynecological Cancers: How Far Has Science Progressed toward Clinical Applications?
by Saikat Mitra, Mashia Subha Lami, Avoy Ghosh, Rajib Das, Trina Ekawati Tallei, Fatimawali, Fahadul Islam, Kuldeep Dhama, M. Yasmin Begum, Afaf Aldahish, Kumarappan Chidambaram and Talha Bin Emran
Cancers 2022, 14(3), 759; https://0-doi-org.brum.beds.ac.uk/10.3390/cancers14030759 - 01 Feb 2022
Cited by 30 | Viewed by 8939
Abstract
In recent years, hormone therapy has been shown to be a remarkable treatment option for cancer. Hormone treatment for gynecological cancers involves the use of medications that reduce the level of hormones or inhibit their biological activity, thereby stopping or slowing cancer growth. [...] Read more.
In recent years, hormone therapy has been shown to be a remarkable treatment option for cancer. Hormone treatment for gynecological cancers involves the use of medications that reduce the level of hormones or inhibit their biological activity, thereby stopping or slowing cancer growth. Hormone treatment works by preventing hormones from causing cancer cells to multiply. Aromatase inhibitors, anti-estrogens, progestin, estrogen receptor (ER) antagonists, GnRH agonists, and progestogen are effectively used as therapeutics for vulvar cancer, cervical cancer, vaginal cancer, uterine cancer, and ovarian cancer. Hormone replacement therapy has a high success rate. In particular, progestogen and estrogen replacement are associated with a decreased incidence of gynecological cancers in women infected with human papillomavirus (HPV). The activation of estrogen via the transcriptional functionality of ERα may either be promoted or decreased by gene products of HPV. Hormonal treatment is frequently administered to patients with hormone-sensitive recurring or metastatic gynecologic malignancies, although response rates and therapeutic outcomes are inconsistent. Therefore, this review outlines the use of hormonal therapy for gynecological cancers and identifies the current knowledge gaps. Full article
(This article belongs to the Special Issue Hormonal Therapy for Gynecological Cancer)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop